Literature DB >> 30307776

Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline.

Scott C Morgan1, Karen Hoffman1, D Andrew Loblaw1, Mark K Buyyounouski1, Caroline Patton1, Daniel Barocas1, Soren Bentzen1, Michael Chang1, Jason Efstathiou1, Patrick Greany1, Per Halvorsen1, Bridget F Koontz1, Colleen Lawton1, C Marc Leyrer1, Daniel Lin1, Michael Ray1, Howard Sandler1.   

Abstract

Entities:  

Year:  2018        PMID: 30307776      PMCID: PMC6269129          DOI: 10.1200/JCO.18.01097

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  97 in total

1.  Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer.

Authors:  Charles N Catton; Himu Lukka; Chu-Shu Gu; Jarad M Martin; Stéphane Supiot; Peter W M Chung; Glenn S Bauman; Jean-Paul Bahary; Shahida Ahmed; Patrick Cheung; Keen Hun Tai; Jackson S Wu; Matthew B Parliament; Theodoros Tsakiridis; Tom B Corbett; Colin Tang; Ian S Dayes; Padraig Warde; Tim K Craig; Jim A Julian; Mark N Levine
Journal:  J Clin Oncol       Date:  2017-03-15       Impact factor: 44.544

2.  Moderate Hypofractionation in High-Risk, Organ-Confined Prostate Cancer: Final Results of a Phase III Randomized Trial.

Authors:  Giorgio Arcangeli; Biancamaria Saracino; Stefano Arcangeli; Sara Gomellini; Maria Grazia Petrongari; Giuseppe Sanguineti; Lidia Strigari
Journal:  J Clin Oncol       Date:  2017-03-29       Impact factor: 44.544

3.  Prostate gland motion assessed with cine-magnetic resonance imaging (cine-MRI).

Authors:  Michel J Ghilezan; David A Jaffray; Jeffrey H Siewerdsen; Marcel Van Herk; Anil Shetty; Michael B Sharpe; Syed Zafar Jafri; Frank A Vicini; Richard C Matter; Donald S Brabbins; Alvaro A Martinez
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-06-01       Impact factor: 7.038

4.  Intensity-modulated radiation therapy (IMRT) for prostate cancer with the use of a rectal balloon for prostate immobilization: acute toxicity and dose-volume analysis.

Authors:  B S Teh; W Y Mai; B M Uhl; M E Augspurger; W H Grant; H H Lu; S Y Woo; L S Carpenter; J K Chiu; E B Butler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-03-01       Impact factor: 7.038

5.  Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer.

Authors:  Alan Pollack; Gail Walker; Eric M Horwitz; Robert Price; Steven Feigenberg; Andre A Konski; Radka Stoyanova; Benjamin Movsas; Richard E Greenberg; Robert G Uzzo; Charlie Ma; Mark K Buyyounouski
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

6.  Stereotactic body radiation therapy for low and intermediate risk prostate cancer-Results from a multi-institutional clinical trial.

Authors:  Raquibul Hannan; Vasu Tumati; Xian-Jin Xie; L Chinsoo Cho; Brian D Kavanagh; Jeffrey Brindle; David Raben; Akash Nanda; Susan Cooley; D W Nathan Kim; David Pistenmaa; Yair Lotan; Robert Timmerman
Journal:  Eur J Cancer       Date:  2016-03-29       Impact factor: 9.162

7.  Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes.

Authors:  Andrew Loblaw; Patrick Cheung; Laura D'Alimonte; Andrea Deabreu; Alexandre Mamedov; Liying Zhang; Colin Tang; Harvey Quon; Suneil Jain; Geordi Pang; Robert Nam
Journal:  Radiother Oncol       Date:  2013-05-03       Impact factor: 6.280

8.  Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.

Authors:  Christopher R King; James D Brooks; Harcharan Gill; Todd Pawlicki; Cristian Cotrutz; Joseph C Presti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-08-26       Impact factor: 7.038

9.  SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer : Toxicity and quality of life assessment.

Authors:  Monika Rucinska; Anna Kieszkowska-Grudny; Sergiusz Nawrocki
Journal:  Strahlenther Onkol       Date:  2016-05-25       Impact factor: 3.621

10.  Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.

Authors:  David Dearnaley; Isabel Syndikus; Helen Mossop; Vincent Khoo; Alison Birtle; David Bloomfield; John Graham; Peter Kirkbride; John Logue; Zafar Malik; Julian Money-Kyrle; Joe M O'Sullivan; Miguel Panades; Chris Parker; Helen Patterson; Christopher Scrase; John Staffurth; Andrew Stockdale; Jean Tremlett; Margaret Bidmead; Helen Mayles; Olivia Naismith; Chris South; Annie Gao; Clare Cruickshank; Shama Hassan; Julia Pugh; Clare Griffin; Emma Hall
Journal:  Lancet Oncol       Date:  2016-06-20       Impact factor: 41.316

View more
  43 in total

1.  Hypofractionated radiotherapy in the real-world setting: An international ESTRO-GIRO survey.

Authors:  Danielle Rodin; Bouchra Tawk; Osama Mohamad; Surbhi Grover; Fabio Y Moraes; Mei Ling Yap; Eduardo Zubizarreta; Yolande Lievens
Journal:  Radiother Oncol       Date:  2021-01-14       Impact factor: 6.280

2.  Dose-volume Histogram-based Predictors for Hematuria and Rectal Hemorrhage in Patients Receiving Radiotherapy After Radical Prostatectomy.

Authors:  Katsuyuki Shirai; Masato Suzuki; Keiko Akahane; Yuta Takahashi; Masahiro Kawahara; Erika Yamada; Masaru Wakatsuki; Kazunari Ogawa; Satrou Takahashi; Kyosuke Minato; Kohei Hamamoto; Kimitoshi Saito; Masashi Oshima; Tsuzumi Konishi; Yuhki Nakamura; Satoshi Washino; Tomoaki Miyagawa
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

3.  Dose-response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control.

Authors:  Rebecca G Levin-Epstein; Naomi Y Jiang; Xiaoyan Wang; Shrinivasa K Upadhyaya; Sean P Collins; Simeng Suy; Nima Aghdam; Constantine Mantz; Alan J Katz; Leszek Miszczyk; Aleksandra Napieralska; Agnieszka Namysl-Kaletka; Nicholas Prionas; Hilary Bagshaw; Mark K Buyyounouski; Minsong Cao; Nzhde Agazaryan; Audrey Dang; Ye Yuan; Patrick A Kupelian; Nicholas G Zaorsky; Daniel E Spratt; Osama Mohamad; Felix Y Feng; Brandon A Mahal; Paul C Boutros; Arun U Kishan; Jesus Juarez; David Shabsovich; Tommy Jiang; Sartajdeep Kahlon; Ankur Patel; Jay Patel; Nicholas G Nickols; Michael L Steinberg; Donald B Fuller; Amar U Kishan
Journal:  Radiother Oncol       Date:  2020-10-07       Impact factor: 6.280

4.  Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies.

Authors:  William C Jackson; Jessica Silva; Holly E Hartman; Robert T Dess; Amar U Kishan; Whitney H Beeler; Laila A Gharzai; Elizabeth M Jaworski; Rohit Mehra; Jason W D Hearn; Todd M Morgan; Simpa S Salami; Matthew R Cooperberg; Brandon A Mahal; Payal D Soni; Samuel Kaffenberger; Paul L Nguyen; Neil Desai; Felix Y Feng; Zachary S Zumsteg; Daniel E Spratt
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-04-06       Impact factor: 7.038

5.  Ten-Year Update of a Randomized, Prospective Trial of Conventional Fractionated Versus Moderate Hypofractionated Radiation Therapy for Localized Prostate Cancer.

Authors:  Vladimir Avkshtol; Karen J Ruth; Eric A Ross; Mark A Hallman; Richard E Greenberg; Robert A Price; Brooke Leachman; Robert G Uzzo; Charlie Ma; David Chen; Daniel M Geynisman; Mark L Sobczak; Eddie Zhang; Jessica K Wong; Alan Pollack; Eric M Horwitz
Journal:  J Clin Oncol       Date:  2020-03-02       Impact factor: 44.544

6.  Comparative toxicity outcomes of proton-beam therapy versus intensity-modulated radiotherapy for prostate cancer in the postoperative setting.

Authors:  Patricia Mae G Santos; Andrew R Barsky; Wei-Ting Hwang; Curtiland Deville; Xingmei Wang; Stefan Both; Justin E Bekelman; John P Christodouleas; Neha Vapiwala
Journal:  Cancer       Date:  2019-09-10       Impact factor: 6.860

7.  Patient-Reported Functional Outcomes After Hypofractionated or Conventionally Fractionated Radiation for Prostate Cancer: A National Cohort Study in England.

Authors:  Julie Nossiter; Arunan Sujenthiran; Thomas E Cowling; Matthew G Parry; Susan C Charman; Paul Cathcart; Noel W Clarke; Heather Payne; Jan van der Meulen; Ajay Aggarwal
Journal:  J Clin Oncol       Date:  2020-01-02       Impact factor: 44.544

8.  Early Tolerance and Tumor Control Outcomes with High-dose Ultrahypofractionated Radiation Therapy for Prostate Cancer.

Authors:  Michael J Zelefsky; Attapol Pinitpatcharalert; Marisa Kollmeier; Debra A Goldman; Sean McBride; Daniel Gorovets; Zhigang Zhang; Melissa Varghese; Laura Happersett; Neelam Tyagi; Margie Hunt
Journal:  Eur Urol Oncol       Date:  2019-10-23

9.  Hypofractionation in prostate cancer radiotherapy: a step forward towards clinical routine.

Authors:  Barbara Vischioni; Rachele Petrucci; Francesca Valvo
Journal:  Transl Androl Urol       Date:  2019-12

10.  Highly hypofractionated intensity-modulated radiation therapy for nonmetastatic prostate cancer with a simultaneous integrated boost to intraprostatic lesions: a planning study.

Authors:  Ryo Ashida; Kiyonao Nakamura; Rihito Aizawa; Hiraku Iramina; Kenji Takayama; Mitsuhiro Nakamura; Takashi Mizowaki
Journal:  Jpn J Radiol       Date:  2021-08-05       Impact factor: 2.374

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.